References

- 1 **Paisan-Ruiz C**, Jain S, Evans EW, *et al*. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. *Neuron* 2004;**44**:595–600.
- 2 **Gilks WP**, Abou-Sleiman PM, Gandhi S, *et al*. A common LRRK2 mutation in idiopathic Parkinson's disease. *Lancet* 2005;**365**:415–6.
- 3 **Shen J**. Protein kinases linked to the pathogenesis of Parkinson's disease. *Neuron* 2004;**44**:575–7.
- 4 **Kay DM**, Kramer P, Higgins D, *et al*. Escaping Parkinson's disease: a neurologically healthy octogenarian with the LRRK2 G2019S mutation. *Mov Disord* 2005;**20**:1077–8.
- 5 **Singleton AB**. Altered alpha-synuclein homeostasis causing Parkinson's disease: the potential roles of dardarin. *Trends Neurosci* 2005;**28**:416–21.

CORRECTION

doi: 10.1136/jnnp.2005.072926corr1

V Jelic, M Kivipelto, B Winblad. Clinical trials in mild cognitive impairment: lessons for the future (*J Neurol Neurosurg Psychiatry* 2006;**77**:429–38).

In table 1 the column with heading Galantamine study 1 (GAL-INT-11) and row with heading ApoE e4, 26.4% galantamine, 29.5% placebo should be 45% galantamine, 47% placebo.

In table 1 the column with heading Galantamine study 2 (GAL-INT-18) and row with heading ApoE e4 24.4% galantamine, 23.5% placebo should be 42% galantamine, 41% placebo.